The pediatric clinical trial market is anticipated to expand at a CAGR of 5.9% during the projected period. The market value is projected to increase from US$ 17,918.1 million in 2024 to US$ 31,661.0 million by 2034. The market was valued at US$ 16,831.0 million in 2023 and grew at a CAGR of 6.5% from 2019 to 2023.
| Attributes | Details |
|---|---|
| Pediatric Clinical Trial Market Value (2024) | US$ 17,918.1 million |
| Projected Market Value (2034) | US$ 31,661.0 million |
| CAGR (2024 to 2034) | 5.9% |
Due to the pediatric population's unmet healthcare needs, there is a sizable product pipeline in the clinical development phase. The pediatric clinical trial market is likely to acquire a strong pipeline for developing new medications shortly.
The market is driven by the rising awareness of pediatric medicines, outsourcing internal clinical trials to CROs, and the rising prevalence of pediatric diseases like diabetes. North America is expected to dominate the market during the projection period.
The growing prevalence of illnesses in the pediatric population bolsters clinical trials and research efforts to develop specific drugs. The demand for pediatric clinical trials is driven by various factors in the global market.
| Attributes | Details |
|---|---|
| Market Value for 2019 | US$ 14,118.8 million |
| Market Value for 2023 | US$ 16,831.0 million |
| Market CAGR from 2019 to 2023 | 4.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Principal Consultant
Key attributes of three closely related markets have been highlighted in the section below. These markets are the pediatric vaccine market, the clinical trial market, and the pediatric clinical trial market. Strong growth and investment opportunities drive market expansion during the forecast period.
Pediatric Clinical Trial Market:
| Attributes | Pediatric Clinical Trial Market |
|---|---|
| Value-based CAGR (2024 to 2034) | 5.9% |
| Growth Factor | Pediatric clinical trials are growing due to a greater emphasis on uncommon pediatric disorders. |
| Market Trend | Demand for specialized pediatric clinical research is driven by personalized medicine. |
| Market Restraint | Illness heterogeneity and small patient populations in pediatrics hinder trial viability and generalizability. |
Clinical Trial Market:
| Attributes | Clinical Trial Market |
|---|---|
| Value-based CAGR (2024 to 2034) | 4.3% |
| Growth Factor | Traditional clinical trial data is increasingly supplemented by real-world evidence. |
| Market Trend | Patient-centric methods are guiding strategies for designing and carrying out trials. |
| Market Restraint | The growing expenses of drug research and trial conduct restrict accessibility and affordability. |
Paediatric Vaccine Market:
| Attributes | Paediatric Vaccine Market |
|---|---|
| Value-based CAGR (2024 to 2034) | 13.1% |
| Growth Factor | Growing awareness of preventative healthcare is compelling the increased demand for pediatric vaccinations. |
| Market Trend | The pediatric vaccination market is growing due to increased focus on immunization programs. |
| Market Restraint | Research on pediatric vaccines is not funded because of the high development costs and lengthy delays. |
| Leading Area | Oncology |
|---|---|
| Market Share in 2024 | 21.8% |
| Leading Sponsor | Industry |
|---|---|
| Market Share in 2024 | 50.7% |
| Leading Phase | Phase 3 |
|---|---|
| Segment CAGR | 46.9% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The pediatric clinical trial market can be observed in the subsequent tables, which focus on the leading economies in India, China, France, Germany, and the United States. A comprehensive evaluation demonstrates that India has enormous opportunities due to its resilient pediatric clinical trial manufacturers.
| Countries | CAGR (2024 to 2034) |
|---|---|
| India | 14.1% |
| China | 11.7% |
| France | 7.1% |
| United States | 3% |
| Germany | 2.5% |
Leading pediatric clinical trial providers, such as Synteract, ICON Plc., Syneos Health, Medpace, Inc., PPD Inc., Premier Research, LabCorp Drug Development, QPS Holding, Pfizer Inc., and The Emmes Company, LLC, as well as IQVIA Inc., dominate the competitive landscape. These pediatric clinical trial vendors use their resources and experience in pediatric healthcare research to drive innovation and determine the sector's course.
Notable industry leaders in pediatric pharmaceutical trials, Synteract, ICON Plc., and Syneos Health, are renowned for their broad skills and all-inclusive services. With their specialist solutions, Medpace, Inc., PPD Inc., and Premier Research enhance the competitive landscape with substantial knowledge. The market is strengthened and diversified by the acquisition of LabCorp Drug Development, QPS Holding, and Pfizer Inc., which enhances the pediatric clinical trial ecosystem.
The Emmes Company, LLC and IQVIA Inc. contribute breadth and depth, guaranteeing a vibrant and competitive atmosphere that promotes ongoing advancement and creativity in pediatric healthcare research.
Notable Developments
| Company | Details |
|---|---|
| Thermo Fisher Scientific Inc. | The National Minority Quality Forum (NMQF), an independent non-profit organization dedicated to research and education, and Thermo Fisher Scientific Inc., a leader in the science service industry worldwide, announced in September 2023 that they collaborated to support the expansion of clinical research to historically underserved patient populations through the NMQF's Alliance for Representative Clinical Trials (ARC). |
| Charles River Laboratories International, Inc. | Charles River Laboratories International, Inc. and Chicago, Illinois-based SAMDI Tech, Inc. announced in January 2022 that they were expanding their strategic alliance. As part of the current relationship, which was formed in 2018, SAMDI Tech clients can use Charles River's collection of lead-like compounds for high-throughput screening (HTS). |
| Pfizer | In August 2022, Pfizer presented positive top-line results from its pivotal Phase 3 study on infants in the United States. The study assessed the efficacy of Pfizer's 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for preventing invasive pneumococcal disease (IPD) in pediatric patients by evaluating its 20 Streptococcus pneumoniae serotypes. |
| Sanofi | Among children with eosinophilic esophagitis (EoE) aged 1 to 11, Sanofi's Phase 3 trial produced encouraging results in July 2022. For children with EoE under the age of 12, there are no recognized treatments. |
The pediatric clinical trial market is set to secure a valuation of US$ 17,918.1 million in 2024.
The demand for pediatric clinical trials is estimated to attain US$ 31,661.0 million by 2034.
Sales of pediatric clinical trials are anticipated to evolve at a 5.9% CAGR through 2034.
From 2019 to 2023, the pediatric clinical trial sales registered a 4.4% CAGR.
The oncology segment is set to achieve a market share of 21.8% in 2024.
The industry segment is expected to hold a 50.7% market share in 2024.
The phase 3 segment is set to achieve a market share of 46.9% in 2024.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Area Development/Innovation Trends 4. Value Added Insights 4.1. Total Number of Pediatric Clinical Trials, By Region 4.2. Clinical Trials Share Analysis, By Areas & By Countries 4.3. Clinical Trials Share Analysis of Disease Areas, By Phases & By Countries 4.3.1. Oncology 4.3.2. Infectious Diseases 4.3.3. Cardiovascular Diseases 4.3.4. Metabolic Diseases 4.3.5. Respiratory Diseases 4.3.6. Diabetes 4.3.7. HIV 4.4. Number of Pipeline Products, By Disease Areas 4.5. Oncology Clinical Trial Starts by Year, 2012 to 2022 4.6. Impact of Artificial Intelligence on Industry Clinical Development Pipeline 4.7. Regulatory Scenario, By Country 4.7.1. Regulatory Frameworks in USA 4.7.2. Regulatory Frameworks in Europe 4.7.3. Regulatory Frameworks in Mexico 4.7.4. Regulatory Frameworks in Brazil 4.7.5. Regulatory Frameworks in Australia 4.7.6. Regulatory Frameworks in New Zealand 4.7.7. Regulatory Frameworks in India 4.7.8. Regulatory Frameworks in Malaysia 4.7.9. Regulatory Frameworks in South Korea 4.7.10. Regulatory Frameworks in Japan 4.7.11. Regulatory Frameworks in Taiwan 4.8. Cost Analysis 4.9. PESTEL Analysis 4.10. PORTER Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Expenditure Outlook 5.1.2. Global Life Expectancy Outlook 5.1.3. R&D Funding By Region 5.1.4. R&D Funding By Country 5.1.5. R&D Spending, By Pharma Players 5.1.6. Top 25 Companies by R&D Spend in 2022 5.1.7. Parent Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Regulatory Initiatives and Incentives 5.2.2. Technological Advancements in Trial Design 5.2.3. Patient-Centric Approaches and Advocacy 5.2.4. Global Collaborations and Partnerships 5.2.5. Increased Focus on Rare Diseases 5.2.6. Inclusive Trial Designs for Diverse Populations 5.2.7. Ethical Considerations and Informed Consent 5.2.8. Advancements in Pediatric Precision Medicine 5.2.9. Integration of Real-World Evidence (RWE) 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022 6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Area 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Million) Analysis by Area, 2018 to 2022 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Area, 2023 to 2033 7.3.1. Oncology 7.3.2. Infectious Diseases 7.3.3. Cardiovascular Diseases 7.3.4. Metabolic Diseases 7.3.5. Respiratory Diseases 7.3.6. Diabetes 7.3.7. HIV 7.3.8. Other Areas 7.4. Market Attractiveness Analysis By Area 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sponsor Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) By Sponsor Type, 2018 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Sponsor Type, 2023 to 2033 8.3.1. Industry 8.3.2. Government Organizations 8.3.3. Non-Government Organizations 8.3.4. Associations 8.3.5. Others 8.4. Market Attractiveness Analysis By Sponsor Type 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Phases 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) By Phases, 2018 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Phases, 2023 to 2033 9.3.1. Phase 1 9.3.2. Phase 2 9.3.3. Phase 3 9.3.4. Phase 4 9.4. Market Attractiveness Analysis By Phases 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis by Region, 2018 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 10.3.1. North America 10.3.2. Latin America 10.3.3. East Asia 10.3.4. South Asia & Pacific 10.3.5. Western Europe 10.3.6. Eastern Europe 10.3.7. Middle East & Africa 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 11.3.1. By Country 11.3.1.1. USA 11.3.1.2. Canada 11.3.1.3. Mexico 11.3.2. By Area 11.3.3. By Sponsor Type 11.3.4. By Phases 11.4. Market Attractiveness Analysis 11.4.1. By Country 11.4.2. By Area 11.4.3. By Sponsor Type 11.4.4. By Phases 11.5. Market Trends 11.6. Drivers and Restraints - Impact Analysis 11.7. Country Level Analysis & Forecast 11.7.1. USA Market Analysis 11.7.1.1. Introduction 11.7.1.2. Market Analysis and Forecast by Market Taxonomy 11.7.1.2.1. By Area 11.7.1.2.2. By Sponsor Type 11.7.1.2.3. By Phases 11.7.2. Canada Market Analysis 11.7.2.1. Introduction 11.7.2.2. Market Analysis and Forecast by Market Taxonomy 11.7.2.2.1. By Area 11.7.2.2.2. By Sponsor Type 11.7.2.2.3. By Phases 11.7.3. Mexico Market Analysis 11.7.3.1. Introduction 11.7.3.2. Market Analysis and Forecast by Market Taxonomy 11.7.3.2.1. By Area 11.7.3.2.2. By Sponsor Type 11.7.3.2.3. By Phases 12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. Brazil 12.3.1.2. Chile 12.3.1.3. Rest of Latin America 12.3.2. By Area 12.3.3. By Sponsor Type 12.3.4. By Phases 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Area 12.4.3. By Sponsor Type 12.4.4. By Phases 12.5. Market Trends 12.6. Drivers and Restraints - Impact Analysis 12.7. Country Level Analysis & Forecast 12.7.1. Brazil Market Analysis 12.7.1.1. Introduction 12.7.1.2. Market Analysis and Forecast by Market Taxonomy 12.7.1.2.1. By Area 12.7.1.2.2. By Sponsor Type 12.7.1.2.3. By Phases 12.7.2. Chile Market Analysis 12.7.2.1. Introduction 12.7.2.2. Market Analysis and Forecast by Market Taxonomy 12.7.2.2.1. By Area 12.7.2.2.2. By Sponsor Type 12.7.2.2.3. By Phases 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. China 13.3.1.2. Japan 13.3.1.3. South Korea 13.3.2. By Area 13.3.3. By Sponsor Type 13.3.4. By Phases 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Area 13.4.3. By Sponsor Type 13.4.4. By Phases 13.5. Market Trends 13.6. Drivers and Restraints - Impact Analysis 13.7. Country Level Analysis & Forecast 13.7.1. China Market Analysis 13.7.1.1. Introduction 13.7.1.2. Market Analysis and Forecast by Market Taxonomy 13.7.1.2.1. By Area 13.7.1.2.2. By Sponsor Type 13.7.1.2.3. By Phases 13.7.2. Japan Market Analysis 13.7.2.1. Introduction 13.7.2.2. Market Analysis and Forecast by Market Taxonomy 13.7.2.2.1. By Area 13.7.2.2.2. By Sponsor Type 13.7.2.2.3. By Phases 13.7.3. South Korea Market Analysis 13.7.3.1. Introduction 13.7.3.2. Market Analysis and Forecast by Market Taxonomy 13.7.3.2.1. By Area 13.7.3.2.2. By Sponsor Type 13.7.3.2.3. By Phases 14. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. India 14.3.1.2. ASEAN Countries 14.3.1.3. Australia & New Zealand 14.3.1.4. Rest of South Asia and Pacific 14.3.2. By Area 14.3.3. By Sponsor Type 14.3.4. By Phases 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Area 14.4.3. By Sponsor Type 14.4.4. By Phases 14.5. Market Trends 14.6. Drivers and Restraints - Impact Analysis 14.7. Country Level Analysis & Forecast 14.7.1. India Market Analysis 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Area 14.7.1.2.2. By Sponsor Type 14.7.1.2.3. By Phases 14.7.2. ASEAN Countries Market Analysis 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast by Market Taxonomy 14.7.2.2.1. By Area 14.7.2.2.2. By Sponsor Type 14.7.2.2.3. By Phases 14.7.3. Australia & New Zealand Market Analysis 14.7.3.1. Introduction 14.7.3.2. Market Analysis and Forecast by Market Taxonomy 14.7.3.2.1. By Area 14.7.3.2.2. By Sponsor Type 14.7.3.2.3. By Phases 15. Western Europe Market 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. UK 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Nordic Countries 15.3.1.8. Rest of Western Europe 15.3.2. By Area 15.3.3. By Sponsor Type 15.3.4. By Phases 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Area 15.4.3. By Sponsor Type 15.4.4. By Phases 15.5. Market Trends 15.6. Drivers and Restraints - Impact Analysis 15.7. Country Level Analysis & Forecast 15.7.1. Germany Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Area 15.7.1.2.2. By Sponsor Type 15.7.1.2.3. By Phases 15.7.2. France Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Area 15.7.2.2.2. By Sponsor Type 15.7.2.2.3. By Phases 15.7.3. Spain Market Analysis 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Area 15.7.3.2.2. By Sponsor Type 15.7.3.2.3. By Phases 15.7.4. Italy Market Analysis 15.7.4.1. Introduction 15.7.4.2. Market Analysis and Forecast by Market Taxonomy 15.7.4.2.1. By Area 15.7.4.2.2. By Sponsor Type 15.7.4.2.3. By Phases 15.7.5. BENELUX Market Analysis 15.7.5.1. Introduction 15.7.5.2. Market Analysis and Forecast by Market Taxonomy 15.7.5.2.1. By Area 15.7.5.2.2. By Sponsor Type 15.7.5.2.3. By Phases 15.7.6. Nordic Countries Market Analysis 15.7.6.1. Introduction 15.7.6.2. Market Analysis and Forecast by Market Taxonomy 15.7.6.2.1. By Area 15.7.6.2.2. By Sponsor Type 15.7.6.2.3. By Phases 15.7.7. United Kingdom Market Analysis 15.7.7.1. Introduction 15.7.7.2. Market Analysis and Forecast by Market Taxonomy 15.7.7.2.1. By Area 15.7.7.2.2. By Sponsor Type 15.7.7.2.3. By Phases 16. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. Russia 16.3.1.2. Hungary 16.3.1.3. Poland 16.3.1.4. Rest of Eastern Europe 16.3.2. By Area 16.3.3. By Sponsor Type 16.3.4. By Phases 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Area 16.4.3. By Sponsor Type 16.4.4. By Phases 16.5. Market Trends 16.6. Drivers and Restraints - Impact Analysis 16.7. Country Level Analysis & Forecast 16.7.1. Russia Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Area 16.7.1.2.2. By Sponsor Type 16.7.1.2.3. By Phases 16.7.2. Hungary Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Area 16.7.2.2.2. By Sponsor Type 16.7.2.2.3. By Phases 16.7.3. Poland Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Area 16.7.3.2.2. By Sponsor Type 16.7.3.2.3. By Phases 17. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Saudi Arabia 17.3.1.2. Türkiye 17.3.1.3. South Africa 17.3.1.4. Other African Union 17.3.1.5. Rest of MEA 17.3.2. By Area 17.3.3. By Sponsor Type 17.3.4. By Phases 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Area 17.4.3. By Sponsor Type 17.4.4. By Phases 17.5. Market Trends 17.6. Drivers and Restraints - Impact Analysis 17.7. Country Level Analysis & Forecast 17.7.1. Saudi Arabia Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Area 17.7.1.2.2. By Sponsor Type 17.7.1.2.3. By Phases 17.7.2. Türkiye Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Area 17.7.2.2.2. By Sponsor Type 17.7.2.2.3. By Phases 17.7.3. South Africa Market Analysis 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Area 17.7.3.2.2. By Sponsor Type 17.7.3.2.3. By Phases 17.7.4. Other African Union Market Analysis 17.7.4.1. Introduction 17.7.4.2. Market Analysis and Forecast by Market Taxonomy 17.7.4.2.1. By Area 17.7.4.2.2. By Sponsor Type 17.7.4.2.3. By Phases 18. Market Structure Analysis 18.1. Market Share Analysis of Top Sponsors 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Branding & Promotional Strategies by Key Stakeholders 19.4. Key Competitive Deep Dive 19.4.1. Charles River Laboratories, Inc. 19.4.1.1. Overview 19.4.1.2. Services Portfolio 19.4.1.3. Key Financials 19.4.1.4. SWOT Analysis 19.4.1.5. Key Developments 19.4.1.6. Sales Footprint 19.4.1.7. Strategy Overview 19.4.2. Covance, Inc 19.4.3. ICON plc (PRA Health Sciences) 19.4.4. IQVIA 19.4.5. Medpace, Inc. 19.4.6. PAREXEL International 19.4.7. Thermo Fisher Scientific (Pharmaceutical Product Development, LLC) 19.4.8. Syneos Health 19.4.9. Wuxi AppTec 19.4.10. Lonza 19.4.11. Bioclinica, Inc 19.4.12. IBM 19.4.13. McKesson Corporation 19.4.14. Oracle Corporation 19.4.15. Veristat 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Pediatric Clinical Trial Market
